Abstract:Abstract Background Mesenchymal stromal cells, which can be obtained in a large quantity from bone marrow easily, are non-hematopoietic multipotent stem cells that cannot differentiate into hematopoietic components in physiological condition. Induced pluripotent hematopoietic stem cells (iP-HSCs) may be an alternative graft source for autologous hematopoietic stem cell transplantation (HSCT) without malignant cell contamination and provide a disease-specific model for studying the underlying pathogenesis. This study aimed to generate putative induced pluripotent stem cells (iPSCs) from bone marrow-derived MSCs (BM-MSCs) using the plasmid pcDNA3.1, only containing OCT4. Methods BM-MSCs with stable ectopic OCT4 expression were established using a conventional plasmid vector, and then cultured in ES medium to form ESC-like clones. The obtained putative iPSCs were divided into two groups and treated with two different growth factor cocktails to induce differentiation into hematopoietic progenitor cells. Furthermore, putative iPSCs were injected subcutaneously into nude mice and the resulting cells were analyzed. Results The generated putative iPSCs were similar to human embryonic stem cells (ESCs) in terms of morphology, surface marker expression, telomerase activity and in vitro differentiation. CD34 + progenitor cells were obtained from the putative iPSCs following treatment with specific factors. The proportion of CD34 + progenitor cells were higher in differentiated cells (16.16 ± 1.27% and 25.40 ± 3.08% at days 14 and 21, respectively) compared to that of untransfected parental BM-MSCs (0.93 ± 0.46%) or undifferentiated cells (1.58 ± 1.29%) (P < 0.05) as determined using flow cytometry. After induction using the second growth factor cocktail and induction process,, the proportion of CD34 + cells reached 31.39 ± 3.60% and 73.68 ± 6.63% at days 14 and 21, respectively. These differentiated cells expressed the mesodermal hematopoietic transcription factor Brachyury. Conclusions This cell induction system developed in this study may provide a possible source of grafts-enriched CD34 + progenitor cells without malignant cell contamination for clinical use and to generate patient-specific cell models for studying of the mechanisms of hematopoiesis and related diseases.

Differentiation and Pro-Angiogenic Potential of Infantile Hemangioma Stem Cells

CD133 Selected Stem Cells from Proliferating Infantile Hemangioma and Establishment of an in Vivo Mice Model of Hemangioma

CD146+ mural cells from infantile hemangioma display proangiogenic ability and adipogenesis potential in vitro and in xenograft models

Isolation, Culture and Characterization of Infantile Hemangioma Stem Cell

Estrogen-Mediated Hemangioma-Derived Stem Cells Through Estrogen Receptor-Alpha For Infantile Hemangioma

Stem cell in infantile hemangioma

Cell Fate Regulation During the Development of Infantile Hemangioma

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening

The role of multipotential stem cells in human infantile hemangioma

JAGGED1 Signaling Regulates Hemangioma Stem Cell–to–Pericyte/Vascular Smooth Muscle Cell Differentiation

Biology of Infantile Hemangioma

Macrophages Contribute to the Progression of Infantile Hemangioma by Regulating the Proliferation and Differentiation of Hemangioma Stem Cells.

Role Of Endothelial-Mesenchymal Transition In The Tumorigenesis Of Infantile Hemangioma

Circulating Mesenchymal Stromal Cells in Patients with Infantile Hemangioma: Evaluation of Their Functional Capacity and Gene Expression Profile

Introduction of OCT4 into Human Bone-Marrow Derived Mesenchymal Stromal Cells Generates Putative Ips Cells with the Potential to Differentiate into CD34+ Hematopoietic Progenitor Cells Ex Vivo

Exosome-derived Mir-196B-5p Facilitates Intercellular Interaction in Infantile Hemangioma Via Down-Regulating CDKN1B

Infantile hemangioma models: is the needle in a haystack?

In Vitro Differentiation of Human Adipose-Derived Mesenchymal Stem Cells into Endothelial-Like Cells

Apelin Receptor Can Act As a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma

Identification of Potential Therapeutics for Infantile Hemangioma via in silico Investigation and in vitro Validation

Insights into the mechanisms of angiogenesis in infantile hemangioma